WHO ICTRP trial
Septimbe clinical trial
IRCT201108014076N3 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT201108014076N3 |
|---|---|
| Public title | Septimbe clinical trial |
| Scientific title | Maximum tolerated dose (MTD) of Septimeb drug; a Phase1 clinical trial |
| Primary sponsor | Pars Roos Biotechnology Co. |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 1 |
| Countries | Iran (Islamic Republic of) |
| Conditions | HIV AIDS. Infectiouse disease;Infectiouse disease |
| Interventions | Four groups, each group consist of three participants enrolled the study. Each group received a constant dose of Septimeb for two weeks. Group1 took 5 mili liter, Group 2 took 6 ml, 7ml in the third and the last group took 8 ml of the… |
| Registration date | Nov 20, 2011 |
| Target size | 12 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: